Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mayo Clinic
Cancer Trials Ireland
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
AstraZeneca
M.D. Anderson Cancer Center
Mayo Clinic
University of Washington
M.D. Anderson Cancer Center
Hoffmann-La Roche
Sichuan University
National Cancer Institute (NCI)
AstraZeneca
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Proton Collaborative Group
National Cancer Institute (NCI)
NYU Langone Health
Ohio State University Comprehensive Cancer Center
Thomas Jefferson University
Thomas Jefferson University